PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup
about
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsLung cancer biomarkers, targeted therapies and clinical assaysTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesMechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaPharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondData Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line EncyclopediaBiomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASLong non-coding RNA CARLo-5 is a negative prognostic factor and exhibits tumor pro-oncogenic activity in non-small cell lung cancer.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Small nucleolar RNA 78 promotes the tumorigenesis in non-small cell lung cancerEpidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinomaMechanisms of resistance to EGFR tyrosine kinase inhibitors.PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cellsThe Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition.KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Phenotype-genotype correlation in multiple primary lung cancer patients in China.Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).Current and future molecular diagnostics in non-small-cell lung cancer.PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.PTEN and PI3K/AKT in non-small-cell lung cancer.Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies.Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap AnalysisBeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactionsCombined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells.New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
P2860
Q26744339-4F6F0264-C5DE-44AA-8350-20C451F8EBF2Q26775396-607DDCC2-047F-4090-909F-9B40BE93AA0CQ27014117-B99CE984-34B2-47F0-9EEE-B8DAEC30189BQ28069900-F3F99990-40DE-40A2-9525-1B6423CD65FEQ28080730-3D9F0EEA-F78A-4025-88DF-C0260BED115BQ28546078-F7D4A21A-5A2B-431A-9F89-0649DB7B7A32Q34023414-312956B5-7966-41DE-B32D-3948635D7130Q34433862-5EE9A10E-4306-43E6-B7E6-5C2A1E55B5F4Q35136424-DBCE7A83-8D5F-4F7E-9EEC-0A237665E23EQ35755323-BD211FA8-5B07-47D5-AE30-1008EC9A9A15Q35885555-91DD9BF4-BB32-42B2-A531-28027EA2F5C8Q36070010-35C5F73C-8D57-470E-8DEE-06887AA59376Q36093612-BD630A01-5F56-41F5-8A28-A82BEE5C9BE0Q36151764-E86E00CA-B6E0-4924-A41D-9EF9C37E46AEQ36238664-2598C80C-0FE0-4C88-BB44-72034C8ABBC6Q36378189-356B62C0-2E12-46CE-B6A7-7F126B579725Q36598758-66DFADD2-BFBA-43CC-9E93-5555AE02CA59Q36844350-35E67E8F-251D-4C24-BFFB-D88E6939598AQ37295372-AE9EC7E8-4B4C-4F79-9103-3CDDBD92F3C6Q37335920-F366CF75-8245-4015-B27E-034EF748A84AQ37353957-6E6CF61A-982B-4579-A4D9-DBC4D727D753Q37379961-C1A47132-FE5E-4707-9EF6-F8B0DA0F24EBQ38358410-264FEA86-CFFE-47DB-82CD-7189049730B0Q38543780-EB2B2340-FECB-4896-B0F4-D9B718A46A55Q38599066-74906AB4-689F-461A-ACCF-230FC8DBFBE4Q38629644-F74DE80D-AD30-4668-AB15-03ABF99BFBB8Q38683041-E317918A-CE92-4262-8BA3-C0A3248043C3Q38852858-B5ED10F9-5023-4AB9-81D7-3199E2BC3156Q38989275-141B787E-F7AE-4DA5-B314-BBB8A17856B4Q41340094-3E6E6756-08F7-45B1-8830-ADB495DBD6ABQ42003695-052FA284-8E19-4989-9CCC-CA1A9CA3C9BCQ42375669-5F17AF3D-A31B-44B9-9F54-325A74BD2368Q45913413-B6EA8EA6-05E1-4A66-9806-3AF6606912A2Q47158976-08B08CA6-E60C-46AB-B2D0-649863EEEF4CQ47159366-D9E98FE0-3A4B-4B92-A6E9-51986921DEDBQ50075111-A391D741-443A-4AEB-ADE2-21F6B0C3A6E3Q53209584-A3B28BE9-80D4-40E3-B4A8-E6636BEDC78EQ55073653-9E29066A-D39F-4589-AC6D-EFD4BEBFBF69
P2860
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
PIK3CA mutations frequently co ...... in EGFR/KRAS wildtype subgroup
@ast
PIK3CA mutations frequently co ...... in EGFR/KRAS wildtype subgroup
@en
type
label
PIK3CA mutations frequently co ...... in EGFR/KRAS wildtype subgroup
@ast
PIK3CA mutations frequently co ...... in EGFR/KRAS wildtype subgroup
@en
prefLabel
PIK3CA mutations frequently co ...... in EGFR/KRAS wildtype subgroup
@ast
PIK3CA mutations frequently co ...... in EGFR/KRAS wildtype subgroup
@en
P2093
P2860
P1433
P1476
PIK3CA mutations frequently co ...... in EGFR/KRAS wildtype subgroup
@en
P2093
Haichuan Hu
Haiquan Chen
Yunjian Pan
P2860
P304
P356
10.1371/JOURNAL.PONE.0088291
P407
P50
P577
2014-02-12T00:00:00Z